Brief: GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBr
21/10/2025 07:00
Oct 21 (Reuters) - GSK plc GSK.L & Spero Therapeutics SPRO.O : GSK: FULL RESULTS OF POSITIVE PIVOTAL PHASE III PIVOT-PO TRIAL EVALUATING TEBIPENEM HBR GSK: DATA SHOW TEBIPENEM HBR’S POTENTIAL AS FIRST ORAL CARBAPENEM ANTIBIOTIC FOR COMPLICATED URINARY TRACT INFECTIONS GSK: TRIAL PRIMARY ENDPOINT MET, SHOWING NON-INFERIORITY OF ORAL TEBIPENEM HBR VERSUS IV TREATMENT GSK: SAFETY PROFILE OF TEBIPENEM HBR GENERALLY SIMILAR TO IMIPENEM-CILASTATIN & OTHER CARBAPENEM ANTIBIOTICS GSK: TO WORK WITH U.S. AUTHORITIES TO INCLUDE TEBIPENEM HBR DATA AS PART OF FILING IN Q4 Source text: [ID:] Further company coverage: GSK.L ((Reuters.Briefs@thomsonreuters.com))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)